TY  - JOUR
AU  - Betts, Matthew J
AU  - Kirilina, Evgeniya
AU  - Otaduy, Maria C G
AU  - Ivanov, Dimo
AU  - Acosta-Cabronero, Julio
AU  - Callaghan, Martina F
AU  - Lambert, Christian
AU  - Cardenas-Blanco, Arturo
AU  - Pine, Kerrin
AU  - Passamonti, Luca
AU  - Loane, Clare
AU  - Keuken, Max C
AU  - Trujillo, Paula
AU  - Lüsebrink, Falk
AU  - Mattern, Hendrik
AU  - Liu, Kathy Y
AU  - Priovoulos, Nikos
AU  - Fliessbach, Klaus
AU  - Dahl, Martin J
AU  - Maaß, Anne
AU  - Madelung, Christopher F
AU  - Meder, David
AU  - Ehrenberg, Alexander J
AU  - Speck, Oliver
AU  - Weiskopf, Nikolaus
AU  - Dolan, Raymond
AU  - Inglis, Ben
AU  - Tosun, Duygu
AU  - Morawski, Markus
AU  - Zucca, Fabio A
AU  - Siebner, Hartwig R
AU  - Mather, Mara
AU  - Uludag, Kamil
AU  - Heinsen, Helmut
AU  - Poser, Benedikt A
AU  - Howard, Robert
AU  - Zecca, Luigi
AU  - Rowe, James B
AU  - Grinberg, Lea T
AU  - Jacobs, Heidi I L
AU  - Düzel, Emrah
AU  - Hämmerer, Dorothea
TI  - Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases.
JO  - Brain
VL  - 142
IS  - 9
SN  - 0006-8950
CY  - Oxford
PB  - Oxford Univ. Press
M1  - DZNE-2020-07825
SP  - 2558-2571
PY  - 2019
AB  - Pathological alterations to the locus coeruleus, the major source of noradrenaline in the brain, are histologically evident in early stages of neurodegenerative diseases. Novel MRI approaches now provide an opportunity to quantify structural features of the locus coeruleus in vivo during disease progression. In combination with neuropathological biomarkers, in vivo locus coeruleus imaging could help to understand the contribution of locus coeruleus neurodegeneration to clinical and pathological manifestations in Alzheimer's disease, atypical neurodegenerative dementias and Parkinson's disease. Moreover, as the functional sensitivity of the noradrenergic system is likely to change with disease progression, in vivo measures of locus coeruleus integrity could provide new pathophysiological insights into cognitive and behavioural symptoms. Locus coeruleus imaging also holds the promise to stratify patients into clinical trials according to noradrenergic dysfunction. In this article, we present a consensus on how non-invasive in vivo assessment of locus coeruleus integrity can be used for clinical research in neurodegenerative diseases. We outline the next steps for in vivo, post-mortem and clinical studies that can lay the groundwork to evaluate the potential of locus coeruleus imaging as a biomarker for neurodegenerative diseases.
KW  - Biomarkers: metabolism
KW  - Humans
KW  - Locus Coeruleus: diagnostic imaging
KW  - Locus Coeruleus: metabolism
KW  - Magnetic Resonance Imaging: methods
KW  - Neurodegenerative Diseases: diagnostic imaging
KW  - Neurodegenerative Diseases: metabolism
KW  - Norepinephrine: metabolism
LB  - PUB:(DE-HGF)16
C6  - pmid:31327002
C2  - pmc:PMC6736046
DO  - DOI:10.1093/brain/awz193
UR  - https://pub.dzne.de/record/141501
ER  -